We May Not ‘Own’ Our Bodies. Should We?
The property law approach to ownership does not draw hard lines with respect to biological materials like tissue.
myriad genetics
-
Read more: We May Not ‘Own’ Our Bodies. Should We? -
Read more: Is Messenger RNA Patent-Eligible? Is Messenger RNA Patent-Eligible?
Amid ongoing patent disputes over the mRNA platform, a significant scientific question remains unanswered: whether mRNA itself even is patent eligible.
-
Read more: A Response to ‘Another Legislative Attempt to Revive Gene Patenting’ A Response to ‘Another Legislative Attempt to Revive Gene Patenting’
Including purified and isolated materials as eligible subject matter under 35 U.S.C. § 101 can benefit patients, researchers, and innovation.
-
Read more: Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna? Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna?
The NIH, which funded much of Moderna’s research on the COVID-19 vaccine, should be assertive in exerting control over the results of this research.
-
Read more: The Civil Rights Challenge to Gene Patenting The Civil Rights Challenge to Gene Patenting
The ACLU mounted an unprecedented challenge the entire practice of gene patenting in America. And, against the odds, they won.
-
Read more: What Ever Happened to NIH’s “Fair Pricing” Clause? What Ever Happened to NIH’s “Fair Pricing” Clause?
It remains to be seen whether Congress or the Administration adopt more decisive measures toward the control of drug prices than they have in the past.
